Meda expands the collaboration with Recordati

Meda expands the collaboration with Recordati

Meda expands the collaboration with Recordati, a European pharma company based
in Italy, by signing a long-term agreement for marketing a new combination
product in Spain - one of the largest European markets. The combination product
consists of lercanidipine (calcium antagonist) and enalapril (an ACE inhibitor)
- two well-known pharmaceutical substances. The product is indicated for the
treatment of high blood pressure. 

Meda already has marketing rights for this combination product in Germany and
Scandinavia. The product launch has started in Germany and will be registered in
Spain through the mutual recognition procedure. 


For more information, please contact:
Anders Lönner, CEO		         tel. +46 8 630 19 72
Anders Larnholt, Investor Relations	tel. +46 8 630 19 62, +46 709 458 878

MEDA AB (publ) is a leading European specialty pharma company that concentrates
on marketing and market-adapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda has
its own affiliates in 25 countries and more than 1,000 employees within
marketing and sales. The Meda share is listed under Large Cap on the OMX Nordic
Stock Exchange. Find out more, visit www.meda.se.